GSKGlaxoSmithKlineRunning, no new patients
Extended Access of Momelotinib in Adults With Myelofibrosis
Primary Myelofibrosis
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 237 (final count)
- Started
- May 3, 2018
- Main results expected
- Dec 11, 2026
- Fully finished
- Dec 29, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants with treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) by severity
Measured over: From study start until each participant transitions to PACT (up to approximately 556 weeks)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT03441113 · record last updated 2026-10-27 · checked 2026-11-09 15:42 UTC